Staphage Lysate
Commercial- Indications
- Canine pyoderma
Company intelligence / Profile preview
Delmont Laboratories, Inc.
Swarthmore, Pennsylvania, United Statesbacteriophage.news ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Commercial
01
Overview
The company produces Staphage Lysate® (SPL), a topical treatment used to manage and control recurrent staphylococcal skin infections in dogs. SPL has been available commercially for decades and remains an option for veterinarians treating chronic canine pyoderma. No recent clinical trial data are publicly available, but the product continues to be distributed.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Bacteriophage lysate
- Industry
- Veterinary
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Delmont Laboratories, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delmont Laboratories, Inc..